サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1671092

重症筋無力症疾患の世界市場：市場規模・シェア・動向、業界分析 (治療の種類別・最終用途別・地域別)、将来予測 (2025年～2034年)

Global Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Use, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
重症筋無力症疾患の世界市場：市場規模・シェア・動向、業界分析 (治療の種類別・最終用途別・地域別)、将来予測 (2025年～2034年)
出版日: 2025年02月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、重症筋無力症疾患の市場規模は2034年までに61億9,000万米ドルに達する見込みです。当レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

重症筋無力症（MG）は、骨格筋、特に眼筋、表情筋、手足などの随意運動を制御する筋肉の衰弱を引き起こす慢性的な自己免疫疾患です。この疾患は、身体の免疫系が神経細胞と筋肉細胞間のコミュニケーションを妨害する抗体を産生し、信号の正常なトランスミッションを妨げることで発症します。

重症筋無力症疾患市場は、世界の有病率の増加、診断技術の進歩、より効果的な治療オプションに対する需要の高まりなど、いくつかの要因によって牽引されています。モノクローナル抗体や免疫療法などの生物学的製剤が開発・承認されたことで、重症化した重症筋無力症に対処する新たな方法が患者に提供されつつあります。

さらに、遺伝子や分子プロファイルに基づいて治療法を調整する個別化医療の動向も注目を集めています。重症筋無力症疾患市場の成長は、患者意識の高まり、臨床試験の拡大、特にアジア太平洋などの新興市場における医療アクセスの改善によっても支えられています。難治性患者のニーズへの対応、治療費の手頃さの改善、先進治療へのアクセスの拡大などが好機です。全体として、より効果的で利用しやすい治療選択肢が出現し続けていることから、市場は着実に成長するものと思われます。

重症筋無力症疾患市場：分析概要

重症筋無力症市場ではコリンエステラーゼ阻害薬が主流を占めており、症状が軽度から中等度の患者のほとんどに対して主要な治療薬として機能しています。しかし、重症例における高度な治療に対する需要の増加により、IVIGやプラズマフェレシスを含む迅速免疫療法の分野が最も急速な成長を示しています。

重症筋無力症疾患市場では、病院が急性増悪から重症例まで包括的な治療を行っているため、病院が最大の市場シェアを占めています。しかし、外来治療へのシフトが進み、専門的治療へのアクセスが向上していることから、診療所部門が最も急成長を遂げています。

北米は、先進的な医療インフラ、高い認知度、患者数の多さにより、重症筋無力症市場を独占しています。しかし、アジア太平洋は、医療アクセスの拡大、診断能力の向上、革新的な治療法の採用増加により、最も急成長している市場です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 重症筋無力症疾患市場の洞察

  • 市場スナップショット
  • 重症筋無力症疾患の市場力学
    • 促進要因と機会
      • 標的療法への注目の高まり
      • 免疫療法の進歩
    • 抑制要因と課題
      • 生存率が低い
  • PESTLE分析
  • 重症筋無力症疾患市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の重症筋無力症疾患市場：治療の種類別

  • 主な調査結果
  • イントロダクション
  • 胸腺摘出術
  • コリンエステラーゼ阻害剤
  • 迅速な免疫療法

第6章 世界の重症筋無力症疾患市場：最終用途別

  • 主な調査結果
  • イントロダクション
  • 科学調査
  • 医薬品・ワクチンの研究開発
  • クローン実験
  • その他

第7章 世界の重症筋無力症疾患市場：地域別

  • 主な分析結果
  • イントロダクション
    • 重症筋無力症疾患市場の評価：地域別 (2020～2034年)
  • 北米
    • 北米：治療の種類別 (2020～2034年)
    • 北米：最終用途別 (2020～2034年)
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療の種類別 (2020～2034年)
    • 欧州：最終用途別 (2020～2034年)
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：治療の種類別 (2020～2034年)
    • アジア太平洋：最終用途別 (2020～2034年)
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：治療の種類別 (2020～2034年)
    • 中東・アフリカ：最終用途別 (2020～2034年)
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療の種類別 (2020～2034年)
    • ラテンアメリカ：最終用途別 (2020～2034年)
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 事業拡大・企業買収の分析
    • 事業拡大
    • 企業買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Alexion Pharmaceuticals（AstraZeneca）
  • Mitsubishi Tanabe Pharma
  • Bristol Myers Squibb
  • Grifols
  • Baxter International
  • CSL Behring
  • UCB
  • Prothena Biosciences
  • Argenx
  • Sanofi
  • Amgen
  • AbbVie
  • Pfizer
  • Roche
  • Novartis
図表

List of Tables:

  • Table 1 Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 3 North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 4 North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 5 U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 6 U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 7 Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 9 Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 10 Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 11 UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 12 UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 13 France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 15 Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 16 Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 17 Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 18 Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 19 Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 23 Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 24 Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 29 China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 30 China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 31 India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 35 Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 36 Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 39 South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 40 South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 41 Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 42 Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 49 UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 51 Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 52 Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 53 South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 54 South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 57 Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 58 Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 59 Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 60 Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 61 Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 63 Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 64 Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Myasthenia Gravis Disease Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Myasthenia Gravis Disease Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Myasthenia Gravis Disease Market, by End-use, 2024 & 2034 (USD Billion)
目次
Product Code: PM1546

The myasthenia gravis disease market size is expected to reach USD 6.19 billion by 2034, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body's immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.

The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.

Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.

Myasthenia Gravis Disease Market Report Highlights

Cholinesterase inhibitors dominate the myasthenia gravis market, serving as the primary treatment for most patients with mild to moderate symptoms. However, the segment of rapid immunotherapies, including IVIG and plasmapheresis, is registering the fastest growth due to increasing demand for advanced therapies in severe cases.

Hospitals hold the largest myasthenia gravis disease market share in the myasthenia gravis treatment market, as they provide comprehensive care for both acute exacerbations and severe MG cases. The clinic segment, however, is experiencing the fastest growth, driven by the increasing shift towards outpatient care and improved accessibility to specialized treatments.

North America dominates the myasthenia gravis market, owing to its advanced healthcare infrastructure, high awareness, and significant patient population. However, Asia Pacific is the fastest growing market, driven by expanding healthcare access, improving diagnostic capabilities, and increasing adoption of innovative therapies.

Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:

By Treatment Type Outlook (Revenue-USD Billion, 2020 - 2034)

  • Thymectomy
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospitals
  • Clinics

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Market Insights

  • 4.1. Myasthenia Gravis Disease Market - Market Snapshot
  • 4.2. Myasthenia Gravis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myasthenia Gravis Disease Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. Thymectomy
    • 5.3.1. Global Myasthenia Gravis Disease Market, by Thymectomy, by Region, 2020-2034 (USD Billion)
  • 5.4. Cholinesterase Inhibitors
    • 5.4.1. Global Myasthenia Gravis Disease Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
  • 5.5. Rapid Immunotherapies
    • 5.5.1. Global Myasthenia Gravis Disease Market, by Rapid Immunotherapies, by Region, 2020-2034 (USD Billion)

6. Global Myasthenia Gravis Disease Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 6.3. Scientific Research
    • 6.3.1. Global Myasthenia Gravis Disease Market, by Scientific Research, by Region, 2020-2034 (USD Billion)
  • 6.4. Medicine and Vaccine R&D
    • 6.4.1. Global Myasthenia Gravis Disease Market, by Medicine and Vaccine R&D, by Region, 2020-2034 (USD Billion)
  • 6.5. Cloning Experiment
    • 6.5.1. Global Myasthenia Gravis Disease Market, by Cloning Experiment, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Myasthenia Gravis Disease Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Myasthenia Gravis Disease Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Myasthenia Gravis Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Myasthenia Gravis Disease Market - North America
    • 7.3.1. North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.3.2. North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.3. Myasthenia Gravis Disease Market - U.S.
      • 7.3.3.1. U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.4. Myasthenia Gravis Disease Market - Canada
      • 7.3.4.1. Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.4. Myasthenia Gravis Disease Market - Europe
    • 7.4.1. Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.3. Myasthenia Gravis Disease Market - UK
      • 7.4.3.1. UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.4. Myasthenia Gravis Disease Market - France
      • 7.4.4.1. France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.5. Myasthenia Gravis Disease Market - Germany
      • 7.4.5.1. Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.6. Myasthenia Gravis Disease Market - Italy
      • 7.4.6.1. Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.7. Myasthenia Gravis Disease Market - Spain
      • 7.4.7.1. Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.8. Myasthenia Gravis Disease Market - Netherlands
      • 7.4.8.1. Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.9. Myasthenia Gravis Disease Market - Russia
      • 7.4.9.1. Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.10. Myasthenia Gravis Disease Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.5. Myasthenia Gravis Disease Market - Asia Pacific
    • 7.5.1. Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.3. Myasthenia Gravis Disease Market - China
      • 7.5.3.1. China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.4. Myasthenia Gravis Disease Market - India
      • 7.5.4.1. India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.5. Myasthenia Gravis Disease Market - Malaysia
      • 7.5.5.1. Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.6. Myasthenia Gravis Disease Market - Japan
      • 7.5.6.1. Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.7. Myasthenia Gravis Disease Market - Indonesia
      • 7.5.7.1. Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.8. Myasthenia Gravis Disease Market - South Korea
      • 7.5.8.1. South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.9. Myasthenia Gravis Disease Market - Australia
      • 7.5.9.1. Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.10. Myasthenia Gravis Disease Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.6. Myasthenia Gravis Disease Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.3. Myasthenia Gravis Disease Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.4. Myasthenia Gravis Disease Market - UAE
      • 7.6.4.1. UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.5. Myasthenia Gravis Disease Market - Israel
      • 7.6.5.1. Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.6. Myasthenia Gravis Disease Market - South Africa
      • 7.6.6.1. South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.7. Myasthenia Gravis Disease Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.7. Myasthenia Gravis Disease Market - Latin America
    • 7.7.1. Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.3. Myasthenia Gravis Disease Market - Mexico
      • 7.7.3.1. Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.4. Myasthenia Gravis Disease Market - Brazil
      • 7.7.4.1. Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.5. Myasthenia Gravis Disease Market - Argentina
      • 7.7.5.1. Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.6. Myasthenia Gravis Disease Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Alexion Pharmaceuticals (AstraZeneca)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Mitsubishi Tanabe Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bristol Myers Squibb
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Baxter International
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. CSL Behring
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. UCB
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Prothena Biosciences
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Argenx
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Sanofi
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Amgen
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. AbbVie
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Pfizer
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Roche
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Novartis
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development